Danaher Corp
NYSE: DHR
Stock price
189.61 USD
(-7.94%) 5 years
Financial Performance
5Y price score: (12)
against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index,
while a score above 100 means it outperformed the S&P 500.
10Y return: 254.4%
US$ Per
Share
Earnings per share
Free cash flow per share
Stock price
By default your notes are visible only to you.
180.0
52-week range
242.8
Your model inputs
| Required return / cost of capital |
| FCFF terminal growth rate |
Valuation
Free Cash Flow Yield
3.9 %
Dividend Yield TTM
0.7 %
Market cap $
$ 134,080.6
Price / Earnings TTM
37.6
Price / Book TTM
2.6
PEG TTM
(8)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
5.6 %
(5.5) %
254.4 %
Free cash flow per share growth
3 %
(1.8) %
59.4 %
Earnings per share growth
(4.7) %
3.1 %
6.3 %
Founded: 1,984
Employees: 61,000
Business Summary:
all figures in USD Millions except per share data
Periods:
View:
Forecast:
Averages
based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.
Analysts
Average Revenue and Net Income forecast estimates from analysts who cover the stock.
Custom
you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.
ㅤ
Please log in / sign up view historical financials. It is free under TopFunds
Light plan.
Increase
Decrease
Total
| Required return / cost of capital |
| FCFF terminal growth rate |
| Free cash flow forecast |
| Terminal value |
| ㅤPV breakdown |
| Enterprise value / PV of FCF |
| ㅤPlus / (Less): Net Debt |
| ㅤLess: preferred stock |
| ㅤLess: minority interest |
| Market cap |
| ㅤNumber of shares |
| Price per share |
Please log in / sign up to calculate fair value based on selected inputs
Latest Earnings Call Takeaways
2025 Q4 (Jan 28, 2026)
1) Strategy & Leadership
- Danaher delivered a strong finish to 2025, with better-than-expected performance across its portfolio.
- The company emphasized disciplined execution, which allowed it to exceed fourth-quarter margin, earnings, and cash flow expectations.
- Leadership expressed confidence in the company's long-term value creation potential, driven by a differentiated portfolio and the Danaher business system.
2) Financial & Segment Results
- For Q4 2025, Danaher reported sales of $6.8 billion, with 2.5% core revenue growth.
- Full-year sales reached $24.6 billion, with core revenue increasing 2%.
- Adjusted diluted net earnings per share were $2.23, up 4% year-over-year.
- Free cash flow for Q4 was $1.8 billion, contributing to a full-year total of $5.3 billion and a conversion ratio of 145%.
- Segment performance:
| Segment | Q4 Core Revenue Growth | Full-Year Growth Outlook |
|------------------|-----------------------|--------------------------|
| Biotechnology | 6% | High single digits |
| Life Sciences | 0.5% | Flat |
| Diagnostics | 2% | Low single digits |
3) Operational & Product Plans
- Danaher launched over 20 new products in bioprocessing, including new bioreactor formats and purification solutions.
- In diagnostics, significant advancements included the FDA clearance for Cepheid's expert GI panel and expansions in Beckman Coulter's assay menu.
- The company expects continued strength in bioprocessing driven by robust demand for monoclonal antibodies and a recovery in pharma R&D spending.
4) Guidance & Outlook / Investor Angle
- For 2026, Danaher anticipates core revenue growth in the range of 3% to 6%.
- Adjusted diluted EPS guidance is set between $8.35 to $8.50.
- The company expects bioprocessing growth to remain strong, while life sciences may see modest improvements.
- Management highlighted potential upside from improved biotech funding and stabilization in academic and government spending.
5) Problems / Headwinds
- The company noted ongoing challenges in academic and government demand, which remained muted.
- There are expectations of continued pressure from policy changes in China affecting diagnostics.
- The transcript lacks detailed figures on specific product performance and competitive landscape insights, which could provide further clarity on market positioning.
Bottom line: Danaher Corporation is positioned for steady growth in 2026, driven by strong fundamentals in bioprocessing and a recovering pharma market, despite headwinds in academic sectors and ongoing geopolitical challenges. The company's robust cash flow and disciplined execution strategy reinforce its potential for long-term shareholder value creation.
Danaher Corp — Financial Overview, Stock Price, Market Cap
Danaher Corp is a company. Founded in 1984. As of April 13, 2026, the company's market capitalization is $134080625790 with a current stock price of $189.61.